Pharma Reshoring Recruitment: Staffing 44,000 New Manufacturing Jobs

The US and the EU are both rebuilding domestic pharmaceutical manufacturing. The US is doing it through trade penalties, the EU through industrial policy and procurement rules, and both moved from proposals to fixed dates within the last four months. Neither has produced a workforce. Companies have announced the sites and committed the money. They haven't hired the people who will run them.

For CDMOs, sponsors and the teams hiring for them, pharmaceutical manufacturing recruitment is now the constraint that will decide which of these sites open on time.

‍

Where the policy now stands

The US Section 232 proclamation signed in April 2026 set tariffs of up to 100% on imported patented medicines and their active ingredients, with relief for companies that committed to domestic production or agreed Most Favored Nation pricing terms. Those tariffs took effect on 31 July 2026 for the companies the proclamation names, and apply from 29 September 2026 to everyone else.

Generic medicines sat outside the regime at first. That changed on 21 July, when the administration announced a phased plan for imported generics: no tariffs for two years from 1 August 2026, 100% from August 2028, then 200% from August 2029 for companies that haven't built plant and equipment in the US. Generics make up roughly 90% of US prescriptions, so the announcement pulled the largest volume segment of the market into the same calculation as branded drugs.

Companies have now announced more than $480 billion of US commitments across 22 manufacturing sites, with around 44,000 new jobs attached, covering APIs, sterile generics, radioligand therapies, biologics and small molecules. Legal advisers tracking client activity put the running total nearer $500 billion, ahead of what most of the industry expected when Section 232 first appeared.

‍

Europe is running a parallel programme

The EU has reached a similar position by different means. On 12 May 2026, the Council and the European Parliament agreed provisionally on the Critical Medicines Act, which requires contracting authorities to apply resilience requirements when they buy critical medicines. It also lets member states reward suppliers in proportion to how much of a medicine and its active ingredients they make inside the EU, and it confirms the criteria for designating strategic projects that create or expand capacity.

The money behind it points to new sites. EU support for onshoring is projected at around €5 billion, with Ireland, Germany and the Netherlands most likely to gain, and Medicines for Europe has asked for a further €4 billion competitiveness fund in the next EU budget to support generic and API production. Announcements have already started. Vetter began first phase construction on a €480 million commercial production site in Saarland during Q2 2026 and expects the plant to run by 2031, alongside a new clinical manufacturing facility in Illinois.

The UK has no equivalent law, and the concern raised in Westminster is that a procurement regime built around resilience elsewhere leaves UK supply chains exposed. For UK based CDMOs and their talent teams, the practical result is competition for the same specialists as EU sites that now have public money behind them.

‍

The arithmetic doesn't work yet

Forty four thousand new roles is the headline. What matters is the pool those roles will come from. Life sciences unemployment in the US was running at 3.1%, with an estimated 60,000 biopharma posts unfilled and a pharmaceutical manufacturing skills gap of around 8% across the industry. Preliminary Bureau of Labor Statistics figures from January 2026 recorded 495,000 open manufacturing jobs across the US economy. Reshoring hiring won't happen in a market with slack in it. It will happen in a market that was already short before the first site was announced.

Build timelines are the one thing working in employers' favour, and only if they use them. Building and qualifying a new GMP facility takes around 32 months on average. Most of the announced US facilities won't start construction until 2026 or 2027, with production beginning between 2028 and 2030. Eli Lilly's $5 billion API plant in Virginia carries a five year build. Johnson & Johnson expects its biologics facility in Wilson, North Carolina to run from around 2030.

That gives hiring leaders a date to work backwards from. It gives every competitor the same date, which is why the sites that staff on time will be the ones that started building pipelines two years early.

Sponsors are also moving work away from Chinese manufacturing partners. Research with US CDMO operations leads found 72% expected more than a quarter of their new commercial manufacturing business between 2026 and 2028 to come from reshoring contracts that Chinese CDMOs held before. Winning that work depends on having the capacity ready and staffed when the sponsor asks.

‍

The roles that break first

Vacancy data from BioPlan Associates shows where the pressure sits across biopharmaceutical manufacturing:

• Process development. 36% of facilities can't fill process development posts. If the process isn't developed, capacity doesn't help.
• Downstream production. 28% can't hire downstream production staff, a shortage that has run for years rather than one this build cycle created.
• Process engineering. 27% don't have enough process engineers, which holds up commissioning and scale up.
• Quality and validation. Every new facility needs QA, QP and validation people in post well before it makes a saleable batch, and every site under construction is hiring them at the same time.

Headline employment figures mislead, because two things are happening at once. Restructuring has continued through 2025 and 2026, with more than 26 biopharma companies announcing cuts in late 2025 alone, while searches for senior regulatory affairs professionals and cell and gene therapy CMC leaders routinely run six to nine months. Cuts in commercial and R&D functions release very few people with the manufacturing and Quality skills the new sites need.

Advanced modalities make it harder again. The cell and gene therapy CDMO market was worth $5.23 billion in 2025 and forecasts put it at $29.49 billion by 2035, growth of close to 19% a year. Companies mostly have to train viral vector and ATMP expertise rather than hire it, because too few people anywhere have done the work.

‍

Tech transfer is the constraint nobody budgets for

A built facility is not a producing facility. Every product moving into a new site needs a formal technology transfer: moving process parameters, analytical methods and quality controls from the sending site to the receiving one, then validating them and getting approval. The work is slow and documentation heavy, and it goes wrong when the people running it haven't done it before.

The FDA's PreCheck programme offers phased technical guidance and earlier pre submission engagement for new domestic plants, and its first cohort covers sterile injectables, APIs and advanced biologics and gene therapy manufacturing across New York, New Jersey, Indiana and North Carolina. Earlier engagement helps the timeline. It also creates demand for regulatory CMC people who can manage that engagement, drawn from the same small pool as everyone else.

Tech transfer recruitment therefore comes first, not midway. Companies that leave it until commissioning lose quarters they can't get back.

‍

What effective workforce planning looks like from here

Working with CDMOs and sponsors on site start up hiring, a few things separate the sites that staff on time from the ones that don't.

Plan from qualification dates, not opening dates. Quality, validation and tech transfer hires need to be in post 12 to 18 months before first commercial production. Work backwards from the qualification milestone, then allow for notice periods that run to three or six months at senior level.

Weigh talent density when choosing a site. Where a company builds decides who it can realistically hire. Established clusters in North Carolina, New Jersey, Indiana, Ireland, Switzerland and Germany cost more in pay and less in time to hire, and the trade off is worth modelling before the site is chosen.

Hire on transferable process skills. Nearby regulated manufacturing sectors hold people who understand batch discipline, deviation management and validation. Roles defined too narrowly around identical previous experience shrink an already small pool, and that is the most common reason searches in this market stall.

Use flexible resource for the ramp. Contract and embedded models cover the commissioning peak without carrying permanent headcount through a build that may still move. Our RPO and embedded recruitment teams usually work here, taking on volume during ramp up and converting priority roles to permanent once the site settles.

Give senior candidates a reason beyond pay. When every employer is building, pay stops separating them. Senior manufacturing and Quality candidates want to know what sits behind the site, what pipeline it will serve and where they go next. Companies that can't explain that lose to companies that can, as we set out in CDMO and CRO talent trends for 2026.

‍

Hiring ahead of the build

Reshoring has produced firm deadlines, committed money and 22 sites with dates attached. It hasn't produced a workforce, and no amount of spending shortens the time it takes to find a process development lead or a QP who has run a technology transfer.

Vector Talent works across the full CDMO landscape, from drug substance and drug product through to biologics and cell and gene therapy, covering CDMO recruitment in commercial, Quality and operations functions and supporting hiring across North America, Europe and APAC. If you're staffing a capacity expansion, a new site or a technology transfer programme, speak to our team about building the hiring plan around your qualification date rather than your opening date.

‍